Adrenocortical carcinoma (ACC) is a rare, heterogenous and highly malignant disease.
Management of ACC is dependent on disease stage with complete surgical resection as the …

Introduction Surgery, followed or not by adjuvant mitotane, is the current mainstay of therapy
for patients with early-stage adrenocortical carcinoma (ACC). Mitotane, either alone or in …

Adrenocortical carcinoma is a heterogeneous and aggressive cancer that originates from
steroidogenic cells within the adrenal cortex. In this study, we have assessed for the …

Simple Summary Preclinical studies have shown an anti-neoplastic effect of progestins
against adrenal cortical carcinoma. Progestins have a positive effect on patient cenesthesia …

Background: Adrenocortical cancer (ACC) is a rare malignancy with a dismal prognosis. The
treatment includes mitotane and EDP chemotherapy (etoposide, doxorubicin, and cisplatin) …

Background: Most patients with testicular germ cell tumors (GCTs) are treated with cisplatin
(CP)-based chemotherapy. However, some of them may develop CP resistance and …

Adrenocortical carcinoma (ACC) is a rare and malignant disease, with more than 50% of
patients developing hormone-secreting tumors. These tumors are genetically …

Circadian dysregulation can be involved in the development of malignant tumors, though its
relationship with the progression of hepatocellular carcinoma is not yet fully understood. We …

Adrenocortical carcinoma (ACC) and pheochromocytoma (PCC) are malignancies
originating from distinct layers of the adrenal gland. ACCs arise from the adrenal cortex, are …

Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis. The
pharmacological approach of ACC is based on mitotane (M) with/without etoposide (E) …